The lab theme is to determine how tyrosine kinases, phosphatases, demethylases and nuclear receptors regulates epigenetic processes that affect cellular homeostasis, immune impairment and cancer. We employ:

ACK1 (TNK2): Immune modulator and oncogene 

WEE1: A novel epigenetic modulator

SHP2 (PTPN11): Role in cancer and LEOPARD syndrome

Androgen Receptor (AR): Prostate cancer and immunity

KDM6A (UTX): Cancer & Multiple sclerosis

Major findings of our lab include:

Nature Communications, 13:6929, 2022

Startup

These studies led to establishment of TechnoGenesys, Inc., focusing on ACK1 inhibitor as an anti-cancer drug.

Phase I Clinical Trial, `PHAROS’ will start (IND#167907)

Current Projects in Lab

  • Epigenetic signaling in dampening of immune response to tumors
  • Characterization of new subsets of T, B cells, macrophages and neutrophils
  • Androgen regulated immune response
  • KDM6A inhibitor in overcoming autoimmune disorders
  • New class of WEE1 inhibitors

Graduate Student Opportunities

We are accepting graduate students from DBBS (Cancer Biology, Molecular Genetics & Genomics, Molecular Cell Biology, Human & statistical Genetics) and Dept of Biomedical Engineering. Contact: nupam@wustl.edu

Postdoctoral Opportunities

We are in recruitment drive. Send your CV to: nupam@wustl.edu

Nupam Mahajan, PhD

Department of Surgery Faculty Profile

Professor of Surgery
Endowed Professor of Cancer Research
Director of Urological Research

Contact:
Washington University, St Louis

Email: nupam@wustl.edu

Phone: 
Office: 314-273-7727 
Lab: 314-273-7759
Fax: 314-272-7771 

Funding Sources:

  • National Institute of Health (NIH)/NCI
    • R01 CA276502
    • R01 CA273054
    • R01 CA285526
    • R01 CA286443
  • Congressionally Directed Medical Research Programs (CDMRP)
  • Bankhead-Coley Biomedical Research Program
  • Elsa U. Pardee Foundation
  • Prostate Cancer Foundation (PCF)
  • Celgene – Committed to improving the lives of patients worldwide